Researchers leveraging generative artificial intelligence have identified new antimicrobial peptides effective against multidrug-resistant bacteria, addressing the critical challenge of antibiotic resistance. This machine learning-driven approach navigates vast chemical spaces to discover candidates active against specific resistant pathogens, potentially accelerating antibiotic development. Complementary efforts include the discovery of narrow-spectrum compounds like enterololin tailored for inflammatory bowel disease pathogens, underscoring AI's transformative impact on antimicrobial drug repurposing and discovery.